All In Biotech

Drug Trial Radar · NCT07828522

F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Safety and Efficacy of F182112 in Combination With Isatuximab and Lenalidomide in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Exploratory Clinical Study

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Oct 9, 2027

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-center, single-arm, exploratory pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of F182112 in combination with isatuximab and lenalidomide in transplant-eligible patients with newly diagnosed multiple myeloma. The study will also explore preliminary proof-of-concept signals of deep responses and minimal residual disease (MRD) negativity with this regimen, thereby informing the design of a subsequent phase II clinical trial.

Conditions

  • Multiple Myeloma (MM)
  • Transplant-eligible Patients

Interventions

  • F182112 Plus Isatuximab and LenalidomideDrug

    Induction treatment phase: F182112: Administered by intravenous infusion. Patients will receive three step-up doses of F182112 at 3 μg/kg, 30 μg/kg, and 180 μg/kg on Days 1, 4, and 8 of Cycle 1, respectively, followed by intravenous administration of F182112 at 180 μg/kg once weekly. Isatuximab: Administered by intravenous infusion at 10 mg/kg. Patients will receive isatuximab on Days 1, 8, 15, and 22 of Cycle 1, and on Days 1 and 15 of each cycle from Cycle 2 to Cycle 6. Lenalidomide: Administered orally at 25 mg on Days 1-21 of each cycle. Maintenance treatment phase: F182112: Administered by intravenous infusion at 180 μg/kg once every 2 weeks. If sustained MRD negativity is maintained for more than 6 months after completion of induction treatment, the investigator may consider adjusting the subsequent dosing frequency to once every 4 weeks. Isatuximab: Administered by intravenous infusion at 10 mg/kg. During the maintenance treatment phase, isatuximab will be administered once

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and outcomes of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) occurring from the initiation of the first study treatment through the end of Cycle 6, or through 30 days after premature discontinuation of study tTime frame: 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.